This study is currently not recruiting participants.

Radiosurgery dosing outcomes on melanoma brain metastases.

Investigating Radiation Dosing Regimens for Melanoma

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to identify optimum radiation dosing regimens with respect to treatment modality, prescribed dose, isodose line prescriptions, tumor characteristics, and immunotherapy in out melanoma patients.

Detailed description of study

The purpose of this study is to identify optimum radiation dosing regimens with respect to treatment modality, prescribed dose, isodose line prescriptions, tumor characteristics, and immunotherapy in out melanoma patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: melanoma
  • Age: 100 years or below
  • Gender: All

This study investigates the best ways to give radiation treatment to patients with melanoma, a type of skin cancer. The study looks at different ways to give the treatment, how much to give, and other factors like the size and type of the tumor and the use of immunotherapy, which is a treatment that helps the body's immune system fight cancer.

Participants in the study will receive different radiation treatments to see which works best. Radiation therapy uses high-energy rays to kill cancer cells. The study will also consider the use of immunotherapy, which involves using medicine to boost the immune system against cancer.

  • Who can participate: Participants must be adults aged 18 and older diagnosed with melanoma. Key eligibility factors include specific tumor characteristics and prior treatment history.
  • Study details: Participants will receive different types of radiation treatments to determine the most effective dosing for melanoma. Some participants may also receive immunotherapy, which helps the immune system fight cancer.
Updated on 19 Feb 2024. Study ID: 1608082504

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team